Focused On-demand Library for Cytosolic beta-glucosidase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Cytosolic beta-glucosidase-like protein 1; Cytosolic galactosylceramidase; Cytosolic glucosylceramidase; Cytosolic glycosylceramidase; Glucosidase beta acid 3; Glucosylceramidase beta 3; Klotho-related protein

Alternative UPACC:

Q9H227; Q32LY7; Q3MIH4; Q53GG8; Q6NSF4; Q8NHT8; Q9H3T4; Q9H4C6


Cytosolic beta-glucosidase, known by alternative names such as Cytosolic beta-glucosidase-like protein 1 and Glucosylceramidase beta 3, plays a pivotal role in the catabolism of glycosylceramides. It exhibits a broad substrate specificity, hydrolyzing galactosylceramides, glucosylsphingosines, and more. This enzyme also shows significant activity towards a variety of dietary glycosides, including phytoestrogens and flavonoids, suggesting a role in xenobiotic metabolism.

Therapeutic significance:

Understanding the role of Cytosolic beta-glucosidase could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.